Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India

Harshith B. Kadnur1, Anivita Aggarwal1, Manish Soneja1, Komal Singh1, Ankit Mittal1, Neeraj Nischal1, Praveen Tirlangi1, Adil Rashid Khan1, Devashish Desai1, Ankesh Gupta1, Arvind Kumar1, Pankaj Jorwal1, Ashutosh Biswas1, Ravindra Mohan Pandey2, Naveet Wig1, Randeep Guleria3

Departments of 1Medicine, 2Biostatistics and 3Pulmonary Medicine and Sleep Disorder, All India Institute of Medical Sciences, New Delhi, India

ABSTRACT

Background: Hydroxychloroquine (HCQ) had generated considerable interest for coronavirus disease 2019 (COVID-19) prophylaxis. We conducted a prospective observational study at a tertiary care hospital in India, with dedicated COVID-19 care facilities.

Objectives: Primary objective was incidence of adverse effects, secondary objective being efficacy in preventing COVID-19.

Methods: Healthcare workers were recruited and grouped based on voluntary HCQ prophylaxis as per national guidelines. Side effects in HCQ group were graded in accordance with national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) version 5.0. At 3–7-week follow-up, groups were compared for COVID-19 exposure, symptoms development and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR results.

Results: Among 358 participants recruited, 216 (60.3%) were males and mean age was 31.2 ± 6.6 years. Chemoprophylaxis was initiated by 258 (72%) participants. After loading dose, 7 (2.7%) reported grade 2 and 1 (0.4%) grade 3 adverse effects. Discontinuation of HCQ due to side effects was reported in 11 (4.3%) participants. Electrocardiogram was done by 50 (19.4%) participants on HCQ; no abnormalities were noted. A total of 106 (41%) among those taking and 63 (63%) among those not taking HCQ were tested for SARS-CoV-2 due to influenza-like illness or significant exposure. Among all participants, 25 (6.9%, 95% confidence interval [CI] 4.3–9.6) developed COVID-19 during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ (P < 0.001). Odds ratio with HCQ intake was 0.34 (95% CI 0.13–0.83, P = 0.01) and the number needed to treat was 12.

Conclusion: HCQ is safe at the recommended dose for pre-exposure prophylaxis of COVID-19.

Keywords: COVID-19, healthcare workers, hydroxychloroquine, pre-exposure prophylaxis, SARS-CoV-2

Introduction

The coronavirus disease 2019 (COVID-19) pandemic has been wreaking havoc across the world since the initial outbreak in Wuhan, China, in December 2019. Healthcare workers (HCWs) have been shown to be at an increased risk of contracting the disease. Reports from various countries suggest that between

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPedknow_reprints@wolterskluwer.com

How to cite this article: Kadnur HB, Aggarwal A, Soneja M, Singh K, Mittal A, Nischal N, et al. Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India. J Family Med Prim Care 2022;11:1140-5.
Attempts were made to repurpose existing drugs as effective therapeutic or prophylactic options for COVID-19. Hydroxychloroquine (HCQ) was used widely for treatment in the early part of the pandemic; however, later it was removed from treatment protocols after results from trials did not demonstrate any efficacy.

HCQ, a safer derivative of chloroquine, has been postulated to have numerous mechanisms of action as an antiviral agent in various studies. These include inhibition of viral attachment, entry into the host cell, new viral particle maturation and spread. Pre-treatment of Vero cells with HCQ versus chloroquine showed that the anti-viral and prophylactic activity of HCQ was better than chloroquine. Due to favourable pharmacokinetics including long half-life, high concentration in the lung tissue and favourable safety profile, HCQ was being studied as a chemoprophylactic agent for COVID-19 in early days of the pandemic. On 22 March 2020, Indian health authorities recommended the use of HCQ pre-exposure prophylaxis in selected high-risk groups including HCWs at a dose of 800-mg loading followed by 400 mg weekly for a total of 8 weeks. This advisory has been the subject of much debate and controversy.

We conducted a prospective observational study to evaluate the incidence of adverse effects as primary objective and efficacy as the secondary objective of HCQ pre-exposure prophylaxis for COVID-19 among HCWs at a tertiary care hospital with dedicated COVID-19 wards and intensive care units.

**Materials and Methods**

This prospective observational study was conducted between 23 April and 11 June 2020 among HCWs (doctors and nursing staff) at a tertiary care hospital in New Delhi, India. More than 2500 confirmed COVID-19 cases were managed at this facility during the study period. Ethical clearance was obtained from the Institute Ethics Committee.

All HCWs were eligible to participate in the study. We approached and invited the HCWs working at the institute to be a part of this study irrespective of their voluntary choice of HCQ chemoprophylaxis for COVID-19. They were enrolled in this study and segregated into two groups based on HCQ intake. HCW symptomatic at the time of starting HCQ was exclusion criteria. After taking informed consent, baseline demographic details, comorbidities and details of other ongoing medications of the participants were documented. Additionally, adverse effects with the loading dose of HCQ and history of any exposure to COVID-19-positive cases were also noted. There was no pre-decided sample size.

All participants were followed up between 3 and 7 weeks after enrolment. Participants in the HCQ group were assessed for compliance, details of any adverse events associated with weekly doses and reasons for discontinuation if applicable. History of exposure to COVID-19 patients, adequacy of personal protective equipment (PPE) during exposure and development of symptoms after exposure were assessed in all the participants. Risk stratification of the contacts was done according to the standard operating procedure (SOP) prepared by institutional hospital infection control committee. Accordingly, high-risk contacts were defined as direct contacts of confirmed cases who performed aerosol-generating procedure without any of the following – N95 mask, eye/face protection and gloves; or if the patients respiratory secretions or saliva come in contact with non-intact skin; or anyone in close proximity (<1 m) of the confirmed case without mask for a duration of more than 15 min; or household contacts of a known positive case. All other contacts were defined as low-risk contacts. Study participants, who fulfilled the criteria as laid down by national guidelines at the time of the study, were tested for COVID-19 by reverse transcriptase-polymerase chain reaction (RT-PCR) of combined nasal and oropharyngeal swab specimens. These criteria recommended testing of any HCW who developed symptoms of influenza-like illness (ILI) or who was exposed to a known COVID-19-positive patient without adequate PPE (between day 5 and 10 after contact). Standard PPE in COVID-19 caring facilities included coverall, N95 mask, goggles, long shoe covers, double gloves and face shield to use during aerosol-generating procedures; PPE for non-COVID-19 caring facilities included gown, goggles, N95 mask and gloves. Electrocardiogram (ECG) was not mandatory as per the initial advisory on the use of HCQ as prophylaxis. Details of ECG done voluntarily by participants were recorded. Participants not willing for follow-up interview were considered as drop-outs.

The primary outcome was the occurrence of adverse events with HCQ. Adverse events were categorized as mild, moderate, severe and life-threatening according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events NCI-CTCAE version 5.0. The efficacy of HCQ in preventing COVID-19 was assessed as a secondary outcome at follow-up.

Data were analysed using STATATA 15.0. Categorical variables were represented as frequency and percentages, and continuous variables as mean (±SD) and median (range). Statistical significance of categorical variables was calculated using Chi-square test, while t-test was used for continuous variables. Association of HCQ with outcome was determined by OR (95% confidence interval [CI]) with potential confounders adjusted in multivariable logistic regression analysis to compute adjusted odds ratio. P value <0.05 was considered as statistically significant.

**Results**

Among 358 participants recruited for the study, HCQ pre-exposure prophylaxis had been voluntarily initiated by 258 (72%) HCWs as shown in [Figure 1].

Among the recruited cohort, 216 (60.3%) were males; 222 (62%) were doctors and 136 (38%) nursing staff. Mean age of participants was 31.2 ± 6.6 years. At least one comorbidity including hypertension, hypothyroidism, diabetes mellitus,
bronchial asthma and others were reported by 54 (15%) participants. The various characteristics of the two groups are compared in Table 1. Doctors, those working in COVID-19 care facilities and those with no comorbidities were more likely to have initiated HCQ pre-exposure prophylaxis.

Among the 258 HCWs on HCQ, 69 (26.7%) reported grade 1 (mild transient) and 7 (2.7%) reported grade 2 (moderate) adverse events [Table 2]. One (0.4%) participant reported mild facial puffiness after taking the first 400 mg of the loading dose and subsequently after 3 h of the second 400 mg dose-reported symptoms suggestive of angioedema (in the form of facial puffiness and mucosal oedema) requiring emergency visit (grade 3 adverse events). None of the participants had grade 4 or 5 adverse event. No significant differences were noted between the groups reporting and not reporting any adverse events. Neurological and gastrointestinal symptoms were the most common adverse events reported. Out of the five (2%) participants in the HCQ group who had reported palpitations, two underwent ECG, both of which were normal. ECG performed in 28 (10.8%) of participants taking HCQ at baseline were normal with corrected QT (QTc) interval ranging between 360 and 430 ms.

At follow-up interview, out of 258 participants on HCQ, 59 (22.8%) discontinued the drug within first 3 weeks, most common reasons being missed weekly doses in 20 (7.7%) participants, perceived lack of adequate evidence favouring HCQ in 21 (8.1%), adverse events in 11 (4.3%) (mostly grade 1) and other reasons in 7 (2.7%). Persistence of adverse effects was reported in 21 (8.1%) of those continuing HCQ, all of which were classified as grade 1 adverse events. ECG was done in 50 (19.4%) participants after initiation of HCQ, none revealed prolonged QTc intervals calculated using Bazzet's formula. During the study period, 62 (24%) in the HCQ group

Table 1: Baseline demographic, follow-up exposure and disease characteristics of healthcare workers (n=358)

| Parameter                                      | Hydroxychloroquine group (258) | No hydroxychloroquine group (100) | P      |
|------------------------------------------------|--------------------------------|-----------------------------------|--------|
| Age in years*                                  | 30.5±6.0                        | 33.2±7.8                          | <0.001 |
| Gender, female                                 | 93 (36%)                        | 49 (49%)                          | 0.02   |
| Comorbidities                                  | 30 (11.6%)                      | 24 (24%)                          | 0.003  |
| Profession                                     |                                |                                   | <0.001 |
| Doctors                                        | 175 (67.8%)                     | 47 (47%)                          |        |
| Nursing officer                                | 83 (32.2%)                      | 53 (53%)                          |        |
| Working area                                   |                                |                                   | <0.001 |
| COVID-19 care facilities                       | 133 (51.5%)                     | 19 (19%)                          |        |
| Non-COVID-19 care facilities                   | 125 (48.5%)                     | 81 (81%)                          |        |
| Symptoms of ILI                                | 62 (24%)                        | 40 (40%)                          | 0.002  |
| Accidental exposure requiring quarantine       | 49 (19%)                        | 40 (40%)                          | <0.001 |
| Tested positive for COVID-19†                  |                                |                                   | <0.001 |
| SARS-CoV-2 positive                            | 10 (3.9%)                       | 15 (15%)                          |        |
| SARS-CoV-2 negative/not required testing as per national guidelines | 248 (96.1%) | 85 (85%) |        |

ILI: Influenza-like illness. All figures in n (%) except *mean±standard deviation. †This value has been calculated from 358 participants as we confirmed from institute database that those who did not fill the follow-up questionnaire either tests were not done/did not test positive.
and 40 (40%) in the non-HCQ group reported ILI symptoms. A significantly greater proportion of participants in the non HCQ group were quarantined \( (P < 0.001) \) [Table 1].

A total of 106 (41%) participants on HCQ and 63 (63%) not taking HCQ were tested for SARS-CoV-2 during the study period as per the national guidelines (ILI symptoms or accidental exposure with a laboratory-confirmed COVID-19 patient without adequate PPE). Among all participants, 25 (6.9%, 95% CI 4.3–9.6) developed COVID-19 disease during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ \( (P < 0.001) \). Majority of the COVID-19-positive cases \( (n = 20, 80\%) \) among the participants were working in non-COVID-19 facilities of the hospital [Table 3].

On multivariable logistic regression analysis, the odds ratio for HCQ was 0.34 (95% CI 0.13–0.83, \( P = 0.01 \)) indicating that odds of developing COVID-19 among those receiving HCQ are 0.34 times as compared to those not taking HCQ. It is protective against developing COVID-19 disease among HCWs [Table 4]. In other words, after taking HCQ, the risk of developing COVID-19 is reduced by 66%. Number needed to treat was 12 to prevent 1 case of COVID-19.

**Discussion**

This prospective observational study was conducted during the early phase of COVID-19 pandemic when several trials on pre- and post-exposure prophylaxis were initiated. The findings in the study suggested safety of HCQ at the recommended doses with 2.7% reporting grade 2 and 0.4% reporting grade 3 adverse events after the loading dose and 4.2% discontinuing the drug due to adverse events. Initial acceptability of the recommendation was good in our cohort with 72% initiating pre-exposure prophylaxis; however, 22.8% discontinued HCQ by the third week of prophylaxis. There was a decreased incidence of COVID-19 among those on pre-exposure prophylaxis with an odds ratio of 0.34 (95% CI 0.13–0.83, \( P = 0.01 \)).

HCQ has been regarded as a safe drug with long experience of use in autoimmune diseases.\(^{[18,19]}\) The incidence of adverse events and discontinuation reported are consistent with that reported in rheumatological conditions like systemic lupus erythematosus;\(^{[18]}\) however, the reports usually are on long-term use of this drug. It has been regarded as a safe drug when used in appropriate dosages for short durations such as in malaria.\(^{[19]}\) Majority of the participants observed neurological and gastrointestinal side effects similar to the literature.\(^{[19,20]}\) QTc prolongation has received attention recently when used for COVID-19 treatment.\(^{[21]}\) ECG was not done by the majority of participants; however, among 50 (19.4%) on HCQ who did get an ECG done, QTc intervals were within normal limits. Also, among two out of five participants who reported palpitations, ECG findings were normal.
HCWs working in COVID-19 care facilities of the hospital and those without comorbidities were more likely to initiate pre-exposure prophylaxis. This may be due to perceived fear of side effects related to drug interactions. A significant proportion (22.8%) discontinued the drug within 3 weeks of initiation, the most common cause being lack of evidence of efficacy. A significant proportion of participants (7.7%) discontinued HCQ as they forgot to take their weekly doses, while 4.3% discontinued due to adverse events. The former may be due to international caution advisories sensitizing the minds of medical professionals.

There was a higher known exposure among HCWs in non-COVID-19 facilities of the hospital which mandated quarantine as per the hospital policy. These were related to accidental exposure to pre-symptomatic and unusual presentation of cases in the non-COVID-19 wards. Also, the level of PPE provided in non-COVID-19 care facility was not the same as that in COVID-19 care facilities. RT-PCR for severe acute respiratory syndrome coronavirus 2 was performed for 47.2% of participants as per the national guidelines and incidence of COVID-19 was found to be 6.9% (95% CI 4.3–9.6). Even though this incidence is similar to that reported from other countries where 3.5–20% of HCWs have been affected with COVID-19, it might be an overestimate in our hospital as HCWs with high-risk exposure may have been more eager to participate in the study.[5–6]

The group not on HCQ had higher known exposure because they were likely to be working in non-COVID-19 care facilities and accidental exposure without adequate PPE skewed the exposure in this group. However, it is interesting to note that out of 25 patients, only 4 had known exposure to the laboratory-confirmed case. Majority of them had unknown exposure, reflecting possible transmission from pre-symptomatic and asymptomatic individuals. This fact became well known as the pandemic progressed. Further, the occurrence of COVID-19 among HCWs in non-COVID-19 care facilities due to known/unknown exposure and few cases among HCWs in the COVID-19 care facilities suggest that the adequate PPE is the most important factor in preventing infection transmission.

In this observational study, HCQ was shown to have protective effect. In a study from Korea evaluating HCQ as post-exposure chemoprophylaxis, none of the participants among 189 patients and 22 HCWs developed COVID-19 even after significant exposure.[23] In another observational study from Spain, no benefits were seen.[24] In the first published randomized trial, comparing HCQ with placebo for post-exposure prophylaxis among 821 COVID-19-exposed participants, no statistically significant difference was found in the number of participants developing COVID-19 within 14 days of exposure. This study had some important limitations. Syndromic diagnosis without subsequent microbiological confirmation was a nonspecific measure of primary outcome overestimating the event rate. It is noteworthy that ~57% of participants were enrolled on days 3 and 4 of exposure, which would be too late to prevent the subsequent infection. A large proportion did not complete the 14-day survey and were lost to follow-up. It was an underpowered study to detect small but clinically meaningful differences, as RT-PCR confirmed cases were only a few.[24] The issue was addressed in subsequent randomized controlled trials, wherein HCQ did not demonstrate any efficacy as prophylaxis for COVID-19.[25–27]

**Limitations**

The study has several important limitations. It was conducted as a prospective observational after the drug was approved by Indian health authorities for pre-exposure prophylaxis among high-risk groups. Further, participation bias might have also crept in probably because more HCWs taking HCQ may have consented for the study; in addition to an overall small sample size. Baseline and follow-up ECG was not performed for all the participants (it was voluntary); however, 50 of the participants on HCQ who had an ECG on follow-up had a normal QTc interval. Hypoglycaemia is an uncommon side effect of HCQ as noted in many case reports. Blood sugar monitoring would have been an objective measure of monitoring it. Another major limitation of our study was that only those symptomatic or with high-risk exposure were tested for SARS-CoV-2 with RT-PCR as per national guidelines. Owing to the non-availability of reliable and validated antibody test kits during the study period, we could not estimate the proportion of asymptomatic infections in the cohort at baseline or follow-up. Finally, the pharmacokinetic parameters related to HCQ absorption or the serum drug levels were not available at this time in the cohort.

**Conclusion**

HCQ was found to be safe at the recommended dose for pre-exposure prophylaxis of COVID-19 and a small proportion discontinued the drug due to adverse events. We observed reduced incidence of COVID-19 among HCW taking HCQ prophylaxis; however, the same has not been validated by RCT.

**Key points**

1. Hydroxychloroquine for pre-exposure prophylaxis against COVID-19 is safe.
2. In observational study, we found HCQ decreased incidence of COVID-19 with odds of 0.34 among HCWs receiving HCQ; however, no efficacy has been seen in multiple RCT.
3. Given the probability of post-vaccination breakthrough infections, the search for an effective post-exposure chemoprophylaxis should continue.

**Acknowledgements**

We would like to thank the Department of Microbiology, AIIMS, for their tireless support in timely testing and reporting for SARS-CoV-2. We would like to appreciate the genuine work of ICMR for guiding health institutes all over the country in managing COVID-19 cases. Last but not the least, we would like to thank all healthcare workers for their hard work and sacrifices in this battle against COVID-19.
Financial support and sponsorship
This work was supported by the intramural funds of the All India Institute of Medical Sciences, New Delhi [COVID-A-12].

Conflicts of interest
There are no conflicts of interest.

References
1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He Q, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
2. Lancet T. COVID-19: Protecting health-care workers. Lancet 2020;395:922.
3. Remuzzi A, Remuzzi G. COVID-19 and Italy: What next? Lancet 2020;395:1225-8.
4. Keeley AJ, Evans C, Colton H, Ankorn M, Cope A, State A, et al. Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020. Euro Surveill 2020;25:2000433.
5. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19: interim WHO solidarity trial results. N Engl J Med 2021;384:497-511.
6. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:1-4.
7. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 2020;55:105960.
8. Wang H, Yang P, Liu K, Gua F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolea-independent endocytic pathway. Cell Res 2008;18:290-301.
9. Kono M, Tatsumi K, Imai AM, Saito K, Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK. Antiviral Res 2008;77:150-2.
10. Yao X, Ye F, Zhang M, Cui C, Huang R, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732-9.
11. Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: The desperate search for effectiveness. Clin Pharmacol Ther 2020;108:766-9.
12. National Taskforce for COVID-19. Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection. 2020. Available from: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinesprophylaxisforSARSCoVInfection.pdf.
13. Rathil S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis 2020;20:1118-9.
14. Tilangi P, Desai D, Khan A, Soneja M. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: A prudent approach. Lancet Infect Dis 2020;20:1119-20.
15. Indian Council of Medical Research. Revised Strategy of COVID19 testing in India (Version 3, dated 20/03/2020). Available from: https://main.icmr.nic.in/sites/default/files/upload_documents/2020-03_20_covid19_test_v3.pdf.
16. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med 2020;173:262-7.
17. Common Terminology Criteria for Adverse Events (CTCAE). 2017;147. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
18. Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol 1999;26:808-15.
19. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From malaria to autoimmunity. Clin Rev Allergy Immunol 2012;42:145-53.
20. Wallace DJ, Tse K, Hanrahan L, Davies R, Petri MA. Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: Survey results from 3127 patients with SLE conducted by the Lupus Foundation of America. Lupus Sci Med 2019;6:000317.
21. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimethaum P, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1036-41.
22. Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents 2020;55:105988.
23. Revollo B, Tebe C, Peñafiel J, Blanco I, Perez-Alvarez N, Lopez R, et al. Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers. J Antimicrob Chemother 2021;76:827-9.
24. Boulware DR, Pulleen MF, Bangdiwala AS, Pastic K, Lofgren SM, Okafor EC, et al. A Randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383:517-25.
25. Abella BS, Jolkinov斯基 EL, Biney BT, Uspel JE, Hyman MC, Frank I, et al. Prevention and treatment of COVID-19 with hydroxychloroquine (PATCH) investigators. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: A randomized clinical trial. JAMA Intern Med 2021;181:195-202.
26. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, et al. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection. A randomized trial. Ann Intern Med 2021;174:344-52.
27. Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastic K, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: A randomized trial. Clin Infect Dis 2021;72:e835-43.